263 related articles for article (PubMed ID: 33750754)
1. Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?
Abdel-Samad N; Sughayar R
Am J Case Rep; 2021 Mar; 22():e928514. PubMed ID: 33750754
[TBL] [Abstract][Full Text] [Related]
2. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune hemolytic anemia, adverse event to venetoclax.
Carriles C; Ordóñez-Fernández L; Arias-Martínez A; Menárguez-Blanc R; Rosado-María MC
Farm Hosp; 2019 Sep; 43(5):166-167. PubMed ID: 31469630
[No Abstract] [Full Text] [Related]
4. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient.
Gentile M; Lucia E; Iorio C; Vigna E; Mazzone C; Morelli R; Bisconte MG; Gentile C; Morabito F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):741-3. PubMed ID: 18064461
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).
Quinquenel A; Willekens C; Dupuis J; Royer B; Ysebaert L; De Guibert S; Michallet AS; Feugier P; Guieze R; Levy V; Delmer A
Am J Hematol; 2015 Mar; 90(3):204-7. PubMed ID: 25428829
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Davids MS; Hallek M; Wierda W; Roberts AW; Stilgenbauer S; Jones JA; Gerecitano JF; Kim SY; Potluri J; Busman T; Best A; Verdugo ME; Cerri E; Desai M; Hillmen P; Seymour JF
Clin Cancer Res; 2018 Sep; 24(18):4371-4379. PubMed ID: 29895707
[No Abstract] [Full Text] [Related]
8. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blombery P; Lew TE; Dengler MA; Thompson ER; Lin VS; Chen X; Nguyen T; Panigrahi A; Handunnetti SM; Carney DA; Westerman DA; Tam CS; Adams JM; Wei AH; Huang DCS; Seymour JF; Roberts AW; Anderson MA
Blood; 2022 Feb; 139(8):1198-1207. PubMed ID: 34469514
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Coutre S; Choi M; Furman RR; Eradat H; Heffner L; Jones JA; Chyla B; Zhou L; Agarwal S; Waskiewicz T; Verdugo M; Humerickhouse RA; Potluri J; Wierda WG; Davids MS
Blood; 2018 Apr; 131(15):1704-1711. PubMed ID: 29305552
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy.
Molica S; Polliack A
Leuk Res; 2016 Nov; 50():31-36. PubMed ID: 27657651
[TBL] [Abstract][Full Text] [Related]
13. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia.
Pamuk GE; Turgut B; Demir M; Tezcan F; Vural O
Am J Hematol; 2006 Aug; 81(8):631-3. PubMed ID: 16906592
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
Crombie J; Davids MS
Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
[TBL] [Abstract][Full Text] [Related]
15. A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
Suzuki T; Miyakoshi S; Nanba A; Uchiyama T; Kawamoto K; Aoki S
J Clin Exp Hematop; 2018 Sep; 58(3):136-140. PubMed ID: 30012921
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
Lacerda MP; Guedes NR; Yamakawa PE; Pereira AD; Fonseca ARBMD; Chauffaille MLLF; Goncalves MV; Yamamoto M; Rodrigues CA
Ann Hematol; 2017 Sep; 96(9):1577-1578. PubMed ID: 28597168
[No Abstract] [Full Text] [Related]
17. Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain.
Galindo-Navarro P; Delgado-García A; Rodríguez-Gil MA; Puerta-Puerta JM
Haematologica; 2023 Aug; 108(8):2261-2264. PubMed ID: 36861400
[No Abstract] [Full Text] [Related]
18. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
20. A rare case of autoimmune hemolytic anemia during venetoclax therapy for relapsed chronic lymphocytic leukemia.
Hadjiaggelidou C; Douganiotis G; Tsirou K; Verrou E; Triantafyllou T; Keramidioti K; Konstantinidou P; Katodritou E
Leuk Lymphoma; 2021 Dec; 62(12):3054-3056. PubMed ID: 34151719
[No Abstract] [Full Text] [Related]
[Next] [New Search]
